S
Sheila J. Gibson
Publications - 15
Citations - 2782
Sheila J. Gibson is an academic researcher. The author has contributed to research in topics: Imiquimod & Cytokine. The author has an hindex of 14, co-authored 15 publications receiving 2695 citations.
Papers
More filters
Journal ArticleDOI
Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
Keith B. Gorden,Kevin S. Gorski,Sheila J. Gibson,Ross M. Kedl,William C. Kieper,Xiaohong Qiu,Mark A. Tomai,Sefik S. Alkan,John P. Vasilakos +8 more
TL;DR: It is demonstrated that TLR7 and TLR8 agonists differ in their target cell selectivity and cytokine induction profile.
Journal ArticleDOI
Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
Sheila J. Gibson,Jana M. Lindh,Tony R. Riter,Raymond M Gleason,Lisa M Rogers,Ashley E Fuller,JoAnn L Oesterich,Keith B. Gorden,Xiaohong Qiu,Scott W McKane,Randolph J. Noelle,Richard L. Miller,Ross M. Kedl,Patricia Fitzgerald-Bocarsly,Mark A. Tomai,John P. Vasilakos +15 more
TL;DR: It is shown that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability, and that resiquimod more effectively matures pDC than either IL-3 or IFN-alpha alone.
Journal ArticleDOI
Cytokine induction by the immunomodulators imiquimod and S-27609.
Traci L. Testerman,John F. Gerster,Linda M. Imbertson,Michael J. Reiter,Richard L. Miller,Sheila J. Gibson,Tamara L. Wagner,Mark A. Tomai +7 more
TL;DR: Kinetic studies with both imiquimod and S‐27609 reveal induction of cytokines as early as 1‐4 h after stimulation and provide insight into the mechanism of cytokine induction by these molecules.
Journal ArticleDOI
Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.
Tamara L. Wagner,Cory L. Ahonen,Aimee M. Couture,Sheila J. Gibson,Richard L. Miller,Rose M.A. Smith,Michael J. Reiter,John P. Vasilakos,Mark A. Tomai +8 more
TL;DR: The data suggest that imiquimod and R-848 may have clinical utility in diseases where cell-mediated immune responses are important and in diseases associated with overexpression of IL-4 or IL-5 such as atopic disease.
Journal ArticleDOI
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
John P. Vasilakos,Rose M.A. Smith,Sheila J. Gibson,Jana M. Lindh,Linda K. Pederson,Michael J. Reiter,Michael H. Smith,Mark A. Tomai +7 more
TL;DR: The above results suggest that the imidazoquinolines R-848 and imiquimod may be attractive compounds for use as vaccine adjuvants and in inhibiting pathological responses mediated by Th2 cytokines.